Celanese Corporation
CE
$58.40
-5.99%
Celanese Corporation is a global chemical company and one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in coatings, adhesives, and various industrial applications. The company is also a major producer of specialty polymers for the automotive, electronics, medical, and consumer end markets, establishing itself as a diversified leader in the chemicals industry. The current investor narrative is focused on the company's recovery from a volatile earnings period, as evidenced by a dramatic 52-week price surge, with attention on margin stabilization in its core Acetyl Chain and Engineered Materials segments and the broader cyclical recovery in industrial demand.…
CE
Celanese Corporation
$58.40
Investment Opinion: Should I buy CE Today?
Rating: Hold. The core thesis is that Celanese presents a high-risk, high-potential-reward situation where compelling valuation metrics are counterbalanced by severe fundamental instability, warranting a neutral stance until earnings visibility improves.
Supporting evidence for this Hold rating includes the deeply discounted Price-to-Sales ratio of 0.49, which is well below industry averages, and the strong trailing free cash flow of $803 million that supports financial flexibility. However, these are offset by the negative trailing P/E of -3.97, the high debt-to-equity of 3.19, and the inconsistent revenue growth, with the latest quarter showing a -7% YoY decline. The stock's powerful +55.8% 3-month rally to near its 52-week high also suggests much of a near-term recovery may already be priced in.
The two biggest risks that could invalidate a Hold thesis are 1) a return to massive quarterly losses, eroding the cash flow buffer, and 2) a failure to reduce leverage, increasing refinancing risk in a higher-rate environment. This Hold would upgrade to a Buy if the company reports two consecutive quarters of positive net income, confirming earnings stabilization, and the PS ratio remains below 0.6. It would downgrade to a Sell if quarterly revenue decline accelerates beyond -10% or if free cash flow turns negative. Relative to its history and chemical peers, the stock appears fairly valued when considering its full risk profile—the deep sales discount is justified by the extreme earnings volatility and high leverage.
Sign up to view all
CE 12-Month Price Forecast
The outlook for CE is bifurcated, with the path determined by earnings stabilization. The base case (50% probability) of volatile consolidation is most likely, as the market requires more than one quarter of profit to believe in a sustained turnaround. The bullish re-rating scenario is plausible but requires flawless execution on debt management and consistent profitability—a high bar given recent history. The bearish scenario, while less probable, carries severe downside risk given the stock's proximity to all-time highs. The stance is neutral due to the high uncertainty; it would upgrade to bullish on confirmation of two consecutive profitable quarters and downgrade to bearish on a return to large losses or a breakdown below key technical support at $60.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celanese Corporation's 12-month outlook, with a consensus price target around $75.92 and implied upside of +30.0% versus the current price.
Average Target
$75.92
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$47 - $76
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, indicating this is not a widely followed large-cap stock, which can lead to higher volatility and less efficient price discovery. The available data shows consensus estimates for EPS of $11.95 and revenue of $8.83 billion, but a consensus price target and explicit buy/hold/sell distribution are not provided in the dataset, preventing a calculation of implied upside or a clear sentiment read. The institutional ratings from recent months show a mixed but generally neutral-to-positive bias, with actions including an upgrade from Wells Fargo to 'Overweight', reaffirmations of 'Buy' from Citigroup and 'Outperform' from Baird, and several firms maintaining 'Neutral' or 'Sector Perform' ratings. The wide dispersion in historical valuation multiples and the lack of a clear price target consensus signal high uncertainty among analysts regarding the company's normalized earnings power and appropriate valuation multiple.
Bulls vs Bears: CE Investment Factors
The investment debate for Celanese (CE) is a classic battle between deep value and fundamental distress. The bull case, currently supported by stronger technical momentum and a compelling valuation discount, hinges on the company's ability to stabilize its wildly volatile earnings and leverage its strong free cash flow to manage debt. The bear case is grounded in the harsh reality of extreme quarterly profit swings, high leverage, and a contracting top line. The single most important tension is whether the current rock-bottom Price-to-Sales ratio of 0.49 represents a profound mispricing of a recovering industrial leader or an accurate reflection of a structurally impaired business. The resolution of this tension depends entirely on the company demonstrating consistent, positive net income in the coming quarters.
Bullish
- Deep Value on Revenue: The stock trades at a trailing Price-to-Sales (PS) ratio of 0.49, representing a significant discount to typical chemical industry averages and at the absolute bottom of its own multi-year historical range. This suggests the market is pricing in a worst-case scenario, creating a potential value opportunity if the company stabilizes its earnings.
- Strong Free Cash Flow Generation: Despite earnings volatility, the company generated $803 million in trailing twelve-month free cash flow, providing robust internal funding for operations and debt service. This strong cash generation underpins the company's financial resilience and supports its 1.55 current ratio.
- Powerful Technical Momentum: The stock has surged +52.5% over the past year and +55.8% over the past three months, significantly outperforming the S&P 500. Trading at 99.5% of its 52-week high of $69.61, it demonstrates strong relative strength and is testing a critical breakout level.
- Positive Analyst Upgrades: Recent institutional actions include an upgrade from Wells Fargo to 'Overweight' and reaffirmations of 'Buy' from Citigroup and 'Outperform' from Baird. This mixed but generally positive bias from analysts suggests a belief in a fundamental recovery.
Bearish
- Extreme Earnings Volatility: Profitability is highly unstable, with quarterly net income swinging from a $1.357 billion loss in Q3 2025 to a $19 million profit in Q4 2025. The trailing net margin is -12.21% and trailing EPS is -$0.25, making traditional valuation difficult and signaling significant underlying volatility.
- High Financial Leverage: The company carries a substantial debt burden with a debt-to-equity ratio of 3.19. This elevated leverage increases financial risk, particularly in a higher interest rate environment, and could pressure earnings through significant interest expenses, which were $214 million in the last quarter.
- Revenue Contraction: Recent Q4 2025 revenue of $2.204 billion represents a -7% year-over-year decline, continuing a trend of inconsistent top-line performance. Without clear segment growth drivers, the recovery narrative lacks a firm foundation in sustained sales growth.
- Valuation Multiples Signal Distress: The negative trailing P/E of -3.97 and an elevated EV/EBITDA of 55.8 reflect severe market skepticism about normalized earnings. While the PS ratio is low, these other metrics indicate the market is discounting the company's ability to generate consistent profits.
CE Technical Analysis
The stock is in a powerful, sustained uptrend, with a 1-year price change of +52.511%, significantly outperforming the S&P 500's +29.04% gain. As of the latest close at $69.24, the price is trading at approximately 99.5% of its 52-week high of $69.605, indicating the stock is at peak momentum and testing a critical resistance level, which could signal either a breakout or a potential overextension. The stock has demonstrated explosive short-term momentum, with a 3-month gain of +55.8056% and a 1-month gain of +8.9536%, both vastly exceeding the S&P 500's respective returns of +4.14% and +9.98%, confirming strong relative strength and accelerating bullish momentum. However, the stock's beta of 0.848 suggests it has been less volatile than the broader market during this ascent, which is atypical for such a sharp rally and may indicate the move is driven by fundamental re-rating rather than speculative frenzy. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $69.605 and support at the 52-week low of $35.13; a decisive breakout above resistance would confirm the bullish thesis and open the door for further gains, while a failure could trigger a pullback towards the $60-$62 consolidation zone seen in late March and April.
Beta
0.81
0.81x market volatility
Max Drawdown
-43.0%
Largest decline past year
52-Week Range
$35-$71
Price range past year
Annual Return
+20.5%
Cumulative gain past year
| Period | CE Return | S&P 500 |
|---|---|---|
| 1m | -8.1% | +11.0% |
| 3m | +6.4% | +5.9% |
| 6m | +41.4% | +9.0% |
| 1y | +20.5% | +30.4% |
| ytd | +38.5% | +7.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CE Fundamental Analysis
Revenue growth has been inconsistent, with the most recent Q4 2025 revenue of $2.204 billion representing a -7% year-over-year decline, continuing a trend of quarterly volatility where revenue has fluctuated between $2.204B and $2.652B over the past two years. The Engineered Materials segment, at $1.277 billion for the period, appears to be the larger revenue contributor compared to the Acetyl Chain's $940 million, though specific growth rates for each segment are not available to determine the primary growth driver. Profitability is highly volatile, as evidenced by a trailing net margin of -12.21% and a quarterly net income swing from a loss of $1.357 billion in Q3 2025 to a profit of $19 million in Q4 2025; the gross margin of 18.77% and operating margin of 8.04% indicate the core business can generate operating profit, but significant one-time charges or impairments have led to large quarterly losses. The balance sheet carries substantial financial leverage with a debt-to-equity ratio of 3.19, which elevates risk, but this is partially offset by robust liquidity with a current ratio of 1.55 and strong cash generation, as evidenced by trailing twelve-month free cash flow of $803 million, providing internal funding capacity for operations and debt service.
Quarterly Revenue
$2.2B
2025-12
Revenue YoY Growth
-0.07%
YoY Comparison
Gross Margin
+0.17%
Latest Quarter
Free Cash Flow
$803000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CE Overvalued?
Given the negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.49 and an Enterprise Value-to-Sales (EV/Sales) of 2.05, indicating the market is valuing the company's revenue stream at a significant discount on an equity basis, though the enterprise value multiple is more standard. Compared to typical chemical industry averages, a PS ratio below 0.5 represents a deep discount, suggesting the market is heavily discounting the revenue base due to profitability concerns and high financial leverage. Historically, the stock's own PS ratio has fluctuated wildly, from a low near 0.49 currently to highs above 9 in 2021; trading at the absolute bottom of its multi-year historical range implies the market is pricing in a worst-case scenario or severe fundamental deterioration, presenting a potential value opportunity if the company can stabilize earnings.
PE
-4.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -74x~61x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
55.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. The company's debt-to-equity ratio of 3.19 indicates a highly leveraged balance sheet, which, combined with quarterly interest expenses exceeding $200 million, creates significant fixed-cost pressure. Earnings volatility is extreme, with a trailing net margin of -12.21% and a quarterly swing from a $1.36 billion loss to a $19 million profit, making forecasting unreliable. While free cash flow of $803 million provides a buffer, revenue concentration in cyclical industrial end-markets and a -7% YoY revenue decline in Q4 2025 expose the company to economic downturns.
Market & Competitive Risks center on valuation compression and cyclicality. Despite the low PS ratio, the stock trades at a 52-week high after a +52.5% rally, leaving it vulnerable to profit-taking and a re-test of support near $60. The stock's beta of 0.848 suggests it is less volatile than the market, but its dramatic rise may have outpaced fundamentals, creating a disconnect. As a chemical company, CE is highly sensitive to industrial demand, input costs, and global trade flows. Regulatory pressures and competitive intensity in its core acetic acid and specialty polymers markets could further pressure already thin operating margins of 8.04%.
Worst-Case Scenario involves a failure to stabilize profitability coinciding with an industrial recession. A sequence of another large quarterly loss, a credit rating downgrade due to its high leverage, and a miss on analyst EPS estimates of $11.95 could trigger a rapid de-rating. This could send the stock re-testing its 52-week low of $35.13, representing a potential downside of approximately -49% from the current price of $69.24. The historical max drawdown of -43.05% provides a benchmark for the magnitude of loss possible in adverse conditions.
FAQ
The key risks, in order of severity, are: 1) Financial Risk: High leverage with a debt-to-equity ratio of 3.19 creates refinancing risk and amplifies losses. 2) Earnings Risk: Extreme quarterly volatility, with a trailing net margin of -12.21%, makes the stock unpredictable and vulnerable to misses. 3) Operational/Cyclical Risk: Revenue is tied to industrial demand, which contracted -7% YoY last quarter, exposing CE to economic downturns. 4) Valuation Risk: The stock trades at a 52-week high after a +52.5% rally, increasing vulnerability to a sharp pullback if the recovery narrative falters.
The 12-month forecast for CE is a wide range reflecting high uncertainty. The base case (50% probability) sees the stock consolidating between $60 and $72 as the market awaits consistent profit proof. The bull case (25% probability), driven by earnings stabilization and debt reduction, could push shares to $75-$85. The bear case (25% probability), triggered by renewed losses, could see a retest of the 52-week low near $35, implying a drop to $35-$50. The most likely scenario is the base case, which assumes the company meets analyst EPS estimates near $11.95 but fails to secure a full valuation re-rating due to lingering volatility concerns.
CE sends mixed valuation signals, but on balance, it appears fairly valued given its risk profile. It is deeply undervalued on a Price-to-Sales basis at 0.49, trading at the bottom of its historical range and a discount to peers. However, it is arguably overvalued on earnings-based metrics, with a negative trailing P/E of -3.97 and a very high EV/EBITDA of 55.8. The market is effectively paying a bargain price for revenue but demanding a large risk premium due to profitability concerns and high leverage. The valuation implies the market expects continued earnings distress, not a rapid recovery.
CE is a high-risk, high-potential-reward stock that may be a good buy only for specific investors. For risk-tolerant investors seeking a deep-value turnaround play in the chemicals sector, the current Price-to-Sales ratio of 0.49 presents a compelling entry point. However, the extreme earnings volatility, high debt load (D/E of 3.19), and recent -7% revenue decline make it a poor choice for conservative or income-focused portfolios. A purchase should be conditioned on a belief that management can stabilize profitability, using the strong $803M free cash flow to deleverage the balance sheet.
CE is unsuitable for short-term trading due to its low beta (0.848) and high fundamental uncertainty, which can lead to unpredictable gaps on earnings news. It is best approached as a long-term (3-5 year) speculative investment for investors betting on a full cyclical and operational turnaround. The long horizon is necessary to allow time for debt reduction, earnings stabilization, and for the deep value represented by the PS ratio to be realized. Given the negligible dividend, this is purely a capital appreciation story requiring patience. A minimum holding period of 18-24 months is suggested to assess whether the recovery thesis is valid.